Table 13.
In vitro mutagenicity assay of GMCT in the Ames test.
| Treatment (μg/plate) | Number of revertant colonies/plate (mean ± SD) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| TA98 (+S9) | TA98 (−S9) | TA100 (+S9) | TA100 (−S9) | TA1535 (+S9) | TA1535 (−S9) | TA1537 (+S9) | TA1537 (−S9) | WP2 uvrA/(pKM101) (+S9) | WP2 uvrA/pKM101 (−S9) | |
| Vehicle control (0) | 25.7 ± 3.1 | 22.3 ± 2.5 | 124.0 ± 3.6 | 123.3 ± 3.5 | 13.7 ± 1.5 | 11 ± 2 | 9.3 ± 2.5 | 6.3 ± 1.5 | 132.3 ± 4.9 | 130.3 ± 3 |
| 100 | 21.3 ± 3.5 | 22.3 ± 1.5 | 122.3 ± 2.5 | 125.3 ± 3.5 | 10.3 ± 1.5 | 11.7 ± 1.5 | 6.3 ± 1.5 | 7 ± 2 | 123 ± 3 | 124 ± 3.6 |
| 266 | 25.3 ± 2.5 | 22.7 ± 2.5 | 123.7 ± 3.1 | 124.3 ± 4 | 9.3 ± 2.1 | 8 ± 2 | 6.7 ± 1.5 | 6.3 ± 1.5 | 124 ± 2.6 | 123 ± 3.6 |
| 707 | 22.7 ± 2.1 | 21 ± 2 | 124.7 ± 2.5 | 125 ± 2 | 8 ± 1 | 8.3 ± 1.5 | 8 ± 2 | 6 ± 1 | 123 ± 1 | 124.3 ± 1.5 |
| 1880 | 22 ± 3.6 | 21 ± 3.6 | 123 ± 2 | 123.3 ± 2.5 | 8.7 ± 1.5 | 10 ± 1 | 7 ± 1 | 5.3 ± 1.5 | 121 ± 1 | 122.3 ± 2.1 |
| 5000 | 22.7 ± 3.5 | 20.7 ± 1.5 | 123 ± 4.4 | 124 ± 3.6 | 8.7 ± 2.1 | 9.3 ± 2.1 | 9 ± 2 | 5.7 ± 2.1 | 120.3 ± 1.5 | 123.3 ± 3.2 |
| Positive control | 549 ± 17.7a | 289.7 ± 13c | 880.3 ± 18.5a | 565.3 ± 14d | 142 ± 8.9a | 152.7 ± 9.3d | 142.3 ± 7.5a | 144 ± 6.6e | 575.7 ± 11.7b | 542.7 ± 9.6f |
a2-Aminoanthracene (4 μg/plate); b2-aminoanthracene (30 μg/plate); c2-nitrofluorence (2 μg/plate); dsodium azide (1 μg/plate); e9-aminoacridine (50 μg/plate); f4-nitroquinoline-1-oxide (4 μg/plate).